A Technical White Paper by DROFEN MACHINERY EQUIPMENT CO., LTD

Author: Jordan Xu, Managing Director

The pre-assembly of injection pens represents a critical and often underestimated stage in the manufacturing lifecycle of advanced drug delivery devices. While the pharmaceutical industry frequently focuses its attention on the final assembly stage due to the immediate presence of the high-value pre-filled drug cartridge, the mechanical foundation of the device is entirely established during pre-assembly. This stage transforms a collection of individual, injection-molded plastic components into a highly precise, functional mechanical mechanism capable of delivering life-saving therapies with absolute accuracy.

 

This white paper distills the engineering lessons learned from DROFEN MACHINERY's development of 160 ppm pre-assembly platforms. Our team initially evaluated multiple architectural approaches - including servo-driven rotary indexing tables and linear transfer systems - before converging on the cam-driven, 130-pallet circulating architecture that now forms the foundation of our platform. This document explains why that architecture was selected, how Kistler piezoelectric force monitoring and Keyence LVDT dimensional verification are integrated to achieve 100% in-process quality assurance, and what validation evidence (including Challenge Parts methodology) is required to satisfy both FDA and EU regulatory expectations.

 

DROFEN MACHINERY is a turnkey system provider delivering automated injection pen assembly lines and pre-filled syringe (PFS) filling systems. The document is intended for pharmaceutical engineers, CDMO operations directors, and equipment procurement teams evaluating automated pre-assembly solutions for insulin pens, GLP-1 delivery devices, and similar cartridge-based injection systems.

According to IQVIA market data, the global GLP-1 receptor agonist market exceeded $50 billion in 2025, with injectable pen-based delivery accounting for over 85% of administered doses. This explosive growth - driven by semaglutide, liraglutide, and tirzepatide therapies - has created an unprecedented demand for pen injector manufacturing capacity. However, the industry's capacity expansion efforts have revealed an uncomfortable truth: the true manufacturing bottleneck is not where most people assume.While final assembly lines receive the majority of capital investment attention (due to the visible presence of the drug cartridge), experienced production directors consistently report that pre-assembly is the actual throughput limiter. The reason is straightforward: a pre-assembly machine must handle 8–12 individual plastic components per pen, each requiring precise orientation, feeding, placement, and verification. A final assembly machine handles only 3–4 components (the pre-assembled mechanism, the cartridge, and the outer housing). The combinatorial complexity of pre-assembly is fundamentally higher.

 

To fully grasp the engineering challenges involved, it is crucial to clearly distinguish between the two primary phases of pen injector manufacturing:

 

Standard, off-the-shelf automation solutions frequently fail when tasked with the rigors of assembling pen injectors at 160 ppm. A typical pen injector may consist of 8 to 12 distinct components, many of which possess critical orientation requirements, asymmetric features, and internal geometries that must align perfectly to ensure accurate dosing.

 

Achieving a stable 160 ppm output while simultaneously maintaining an Overall Equipment Effectiveness (OEE) of ≥85% and a yield of >95% is not merely a matter of running motors faster. It requires a specialized, holistic architectural approach that seamlessly integrates robust material handling, intelligent buffering, and multi-layered, real-time quality verification at every step of the process.

 

The financial implications of a failed pre-assembly process are severe. If a defective pre-assembled unit passes undetected into the final assembly line, it will inevitably result in a failure during the final functional test. At that point, the high-value pre-filled drug cartridge has already been integrated. Rejecting the pen means rejecting the drug. For therapies like GLP-1 agonists, where the drug product is exceptionally expensive (often exceeding $5–$10 per cartridge), even a minor increase in the rejection rate at final assembly due to pre-assembly defects can cost a manufacturer millions of dollars annually.

To sustain a stable, continuous output of 160 pens per minute, the system utilizes a sophisticated pallet-based transfer mechanism. A critical design feature of this architecture is the incorporation of a large circulating buffer, typically consisting of approximately 130 pallets moving through the system at any given time.

 

This extensive pallet buffer is absolutely essential for decoupling the individual assembly and inspection stations. In a rigidly linked system, a minor fault at one station would cause the entire line to halt instantly. By contrast, the 130-pallet buffer allows upstream stations to continue operating briefly, accumulating work-in-progress, while downstream stations continue processing the available buffer. This decoupling prevents minor faults from causing complete line stoppages, thereby significantly improving the system's OEE.

 

For high-speed cyclic operations, a common debate arises between the use of mechanical cam-driven systems versus servo-driven robotic arms. At 160 ppm, the transport mechanism must execute rapid, highly precise movements continuously-extend, grip, transfer, release, retract-within fractions of a second.

 

While servo systems offer flexibility, mechanical cam-driven systems are vastly superior for this specific application. Cam profiles physically define the position, velocity, and acceleration of the tooling at every microsecond of the cycle. They provide inherently repeatable motion paths, completely eliminating the risks associated with servo tuning drift, encoder feedback loss, or the accumulation of gearbox backlash over millions of cycles.

 

The Siemens-based control system governing the platform is designed to support multiple operational modes: Auto, Semi-Auto, Manual, and Jog. This flexibility is critical during the Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) phases, allowing validation engineers to isolate specific stations and thoroughly test edge cases without running the entire machine at full speed.

 

The selection of a cam-driven architecture over a fully servo-driven system was not an obvious choice. Our initial prototype testing in 2022 evaluated a 16-station servo-driven rotary indexing table. While the servo approach offered theoretical flexibility in motion profiles, we encountered three critical limitations at speeds above 120 ppm:

 

First, the cumulative positioning error across 16 independent servo axes created station-to-station alignment drift that exceeded our ±0.02 mm budget for Keyence LVDT measurement repeatability.

Second, the servo system's inherent compliance (elasticity in the drive train) introduced vibration at the measurement stations, corrupting Kistler force data with mechanical noise.

Third, the servo architecture required significantly more floor space due to the larger motor housings and cable routing requirements - a critical constraint for cleanroom installations where every square meter carries a premium.

 

The cam-driven architecture solved all three problems simultaneously: mechanical synchronization eliminates cumulative positioning error, the rigid cam profile provides vibration-free motion at measurement stations, and the compact mechanical design reduces the machine footprint by approximately 30% compared to the equivalent servo solution.

A modern pen injector comprises numerous small, complex components. Each of these parts presents unique feeding, orientation, and handling challenges that must be overcome to maintain a 160 ppm throughput.

 

To support continuous high-speed operation, the system employs advanced automated bulk feeding strategies. Vibratory bowl feeders and linear tracks are custom-tooled for each specific component, accounting for the specific center of gravity, geometric asymmetries, and surface finish of each part. The escapement mechanisms singulate parts from the continuous feed track and present them in the exact orientation required by the pick-and-place tooling, operating reliably at 160 cycles per minute.

 

High-volume pharmaceutical manufacturing often requires rapid changeovers between different product variants. To facilitate this, the DROFEN system is designed with advanced auto-emptying capabilities. During batch changeovers, the system can automatically purge residual materials from the vibratory bowls and linear tracks, significantly reducing manual changeover times and minimizing the risk of cross-contamination.

 

The outer body and user-facing components must remain visually pristine. Scratches or dents not only impact the perceived quality of the device but can also lead to rejection during final inspection. The DROFEN system utilizes specialized anti-scratch grippers and controlled handling techniques throughout the entire assembly process. Parts are never allowed to tumble uncontrollably or impact hard surfaces.

At a sustained speed of 160 ppm, relying on simple binary "presence" detection is woefully insufficient. DROFEN's pre-assembly platform employs a comprehensive philosophy utilizing high-precision position verification to detect a wide spectrum of potential defects.

 

Using Keyence LVDT (Linear Variable Differential Transformer) sensors, the system continuously verifies the seating height of critical components and sub-assemblies. For instance, the system checks the height of the Plunger Cap, the Drive Sleeve, and the fully integrated Mechanism Sub-Assembly.

 

These measurements must fall within strict, pre-defined tolerance windows, often measured in hundredths of a millimeter. Any deviation-indicating an improperly seated part, a missing internal component, or a dimensional anomaly-triggers an immediate rejection. LVDT technology is preferred here over vision for depth measurement due to its extreme accuracy and immunity to variations in component color or lighting conditions.

 

Advanced vision systems, typically utilizing high-resolution cameras and specialized lighting arrays, are strategically deployed to detect subtle orientation errors. Beyond simply detecting an inverted Lead Screw, the system verifies the rotational alignment of internal components. It ensures that specific geometric features, such as gear teeth alignments, keyways, and internal indicator marks, are correctly positioned relative to one another before the assembly proceeds to the next station.

 

Before the completed pre-assembled unit is unloaded from the pallet, the system performs a final, comprehensive verification. Crucially, it verifies the "Zero Marking" alignment. This involves using a vision system to confirm that the zero dose indicator printed on the internal mechanism perfectly aligns with the center of the viewing window on the outer body. This check is paramount for ensuring downstream dosing accuracy and patient safety.

While geometric verification (confirming parts are present, correctly oriented, and at the right height) is essential, it alone cannot guarantee the functional performance of the pen injector. Pre-assembly must also incorporate rigorous, real-time force and torque monitoring to validate the mechanical integrity of the device.

 

During the critical assembly of the Mechanism Sub-Assembly into the Outer Body, the system continuously monitors the applied press force. This is achieved using high-precision Kistler piezoelectric load cells.

 

If the force required to seat the assembly falls outside the defined acceptable envelope, the unit is immediately flagged and rejected. This monitoring detects hidden issues such as oversized internal components, excessive friction due to lack of lubrication, or improper seating that could lead to mechanical failure during patient use, even if the final geometric height appears correct to the Keyence LVDT sensors.

 

The Dose Setting Knob (DSK) is the primary interface between the patient and the device. Its operation must be smooth, consistent, and require a specific amount of torque. The DROFEN system performs functional torque verification by physically tightening and loosening the DSK during the assembly process using a servo-driven torque transducer. This operation captures traceable force data, ensuring that the torque required to set a dose falls strictly within the specified ergonomic and functional limits.

Maintaining a stable 160 ppm throughput requires not only high-speed assembly but also intelligent handling of defective units. The system must be able to identify, track, and segregate bad parts without disrupting the continuous flow of good production.

 

Every pallet in the 130-pallet buffer system is equipped with an RFID tag or tracked via a highly reliable shift register logic in the Siemens PLC. As a pallet moves from station to station, its status (Empty, In Progress, Good, Bad) is continuously updated.

 

If a station detects a defect (e.g., via Keyence LVDT, vision inspection, or Kistler force monitoring), the specific pallet is electronically flagged as "Bad." Subsequent assembly stations will read this flag and bypass the defective unit, preventing further components from being wasted on a known bad assembly.

 

The control system utilizes sophisticated consecutive error counters. If a specific station generates multiple consecutive rejects (for example, due to a persistently jammed component in a feed track), the system will intelligently halt only that specific section of the line. This prevents the continuous generation of waste while allowing other sections to clear their buffers safely.

The system is governed by a Siemens industrial PLC with an industrial panel PC providing a bilingual operator interface. The control system manages real-time machine control, pallet tracking, part status management, and station interlock logic.

 

In pre-assembly, 21 CFR Part 11 compliance serves a fundamentally different purpose than in final assembly. There is no drug product present - the compliance imperative is to guarantee that the mechanical integrity data (press forces, dimensional measurements, torque values) recorded during pre-assembly can be traced back to each individual pen mechanism months or years later during post-market surveillance or complaint investigation.

 

Force Data Integrity: Every Kistler press-force curve is stored as a complete waveform (not merely a pass/fail flag), linked to the specific pallet ID and timestamp. During a recent FAT validation, our engineering team verified data integrity across 50,000 consecutive press cycles - achieving 99.97% successful data capture with zero orphaned records.

 

Dimensional Measurement Traceability: Each Keyence LVDT measurement is recorded to 0.001 mm resolution and associated with the component's unique pallet position. This granularity enables root-cause analysis when downstream functional test failures occur - engineers can retrospectively examine whether a specific dimensional trend in pre-assembly correlates with the failure mode.

 

Access Control: The system enforces role-based access with automatic session timeout. Critically, recipe parameter boundaries (force limits, LVDT acceptance windows) can only be modified by validation-level users - preventing production operators from inadvertently widening tolerances to reduce reject rates.

 

The recipe management system stores all process-critical parameters for each pen variant in a validated, version-controlled recipe structure. Recipe parameters include: Keyence LVDT acceptance ranges for each measurement point, Kistler force envelope boundaries, press speed and stroke distance, and vision inspection reference images.

 

Recipe changes require supervisor-level access and are fully captured in the audit trail. The system enforces a "recipe lock" during production-preventing any parameter modification while a batch is active.

 

DROFEN delivers every pre-assembly system with a comprehensive validation documentation package structured according to the GAMP 5 V-model lifecycle. A typical documentation package comprises 800–1,200 pages across URS, FDS, HDS, SDS, FAT protocols, and SAT protocols. During a recent project for a leading European CDMO establishing GLP-1 pen manufacturing capability, the FAT phase alone generated 47 individual test protocols covering mechanical performance, electrical safety, software functionality, and process capability. The system demonstrated a Cpk > 1.67 for all critical Keyence LVDT measurement points and achieved a 100% detection rate across all 19 categories of Challenge Parts during the OQ phase.

The pre-assembly platform accommodates cartridge-based injection pens across the full range of current and emerging therapies, including insulin (daily dosing) and GLP-1 receptor agonists (weekly dosing) in both 1.5 mL and 3.0 mL formats.

 

The Siemens HMI supports multiple product recipes. When transitioning between different pen variants, the operator simply selects the appropriate recipe from the HMI. The system automatically adjusts the electronic parameters (such as Keyence LVDT tolerance windows and Kistler force thresholds), minimizing the need for manual, error-prone mechanical adjustments.

Pen injector pre-assembly typically operates in an ISO 8 (Class 100,000) or ISO 7 (Class 10,000) cleanroom environment. The equipment design must accommodate these environmental constraints without compromising production efficiency.

 

DROFEN's pre-assembly platform is designed with cleanroom operation as a primary requirement. All external surfaces are constructed from stainless steel (SUS304) or anodized aluminum with smooth, wipe-down-compatible finishes. Cable routing is fully enclosed within the machine frame. The system manages particle generation through several design strategies: vibratory bowl feeders are enclosed with HEPA-filtered extraction; cam mechanism lubrication uses cleanroom-compatible greases with low outgassing characteristics; and the reject station incorporates local extraction to prevent rejected parts from contaminating the production path.

DROFEN MACHINERY does not deliver pre-assembly equipment as an isolated unit. For customers seeking complete manufacturing capability, DROFEN provides both the 160 ppm pre-assembly platform and the subsequent 160 ppm final assembly line as a single integrated package.

This turnkey approach eliminates the multi-vendor coordination risk that frequently delays CDMO production line projects. By supplying both platforms, DROFEN ensures seamless mechanical integration, optimized dimensional tolerances across the entire device lifecycle, and a unified Siemens control architecture. It ensures that the pre-assembly machine is perfectly tuned to produce the exact input required by the final assembly machine.

 

Typical Project Timeline:

When evaluating pre-assembly equipment, procurement teams frequently focus on the initial capital expenditure (CAPEX). However, the operational cost impact of poor pre-assembly verification far exceeds the initial equipment price differential over the lifetime of the system.

A pre-assembly system with inadequate verification capabilities will inevitably pass defective units downstream to the final assembly line. At final assembly, a rejected unit results in the loss of the high-value, pre-filled drug cartridge. If the drug cartridge cost is $6.00 per unit (a conservative estimate for GLP-1 formulations), the financial penalty for a poor pre-assembly process is severe.

 

The investment in advanced Keyence LVDT dimensional verification and Kistler force monitoring at the pre-assembly stage pays for itself rapidly by protecting the drug product downstream. A system that reliably identifies and rejects mechanical defects before the cartridge is inserted will save millions of dollars in lost drug product over its lifecycle.

Q: What is the typical throughput for pen injector pre-assembly equipment?

A: The stable running speed for a high-performance pen injector pre-assembly system is 160 pens per minute (ppm). DROFEN's pre-assembly platform is engineered to maintain this 160 ppm throughput while achieving an Overall Equipment Effectiveness (OEE) of ≥85% and a yield greater than 95%, utilizing a 130-pallet circulating buffer architecture to maximize efficiency.

 

Q: Why is force and torque monitoring necessary in pre-assembly?

A: Geometric verification is insufficient for functional reliability. Pre-assembly systems must incorporate force and torque monitoring to verify mechanical integrity. DROFEN's equipment uses Kistler piezoelectric load cells to monitor the press force of internal mechanisms, ensuring that the required operating forces fall within validated specifications.

 

Q: What is the role of LVDT sensors in the pre-assembly process?

A: Keyence LVDT sensors are used for ultra-precise height and seating verification. They confirm that internal components are fully seated to within hundredths of a millimeter. This is critical for ensuring the final dosing accuracy of the pen injector.

 

Q: How does the system manage defective parts without stopping production?

A: The system utilizes a 130-pallet architecture with intelligent stop logic. If a station detects a defect (e.g., via Keyence LVDT or vision inspection), the specific pallet is flagged. The defective unit is tracked and automatically segregated at a dedicated reject station, allowing the rest of the 160 ppm production flow to continue uninterrupted.

 

Q: How does the system comply with 21 CFR Part 11?

A: Compliance is achieved through a robust Siemens control architecture that includes hierarchical, password-protected user access, an immutable electronic audit trail that records all significant events with secure timestamps, and the generation of comprehensive Electronic Batch Records (EBR) that adhere to ALCOA+ data integrity principles.

 

Q: Can one pre-assembly line handle multiple drug products (insulin, GLP-1)?

A: Yes. DROFEN's pre-assembly platform accommodates multiple pen variants through recipe-based changeover. Each variant has a validated recipe on the Siemens HMI that defines Keyence LVDT acceptance ranges, Kistler force envelope boundaries, and vision inspection reference images.

 

Q: What are the risks of buying pre-assembly and final assembly equipment from different suppliers?

A: Buying pre-assembly and final assembly equipment from different suppliers creates an "integration gap" that typically increases rejection rates during commissioning. The root cause is dimensional mismatch. At $6 per cartridge, a 0.5% increase in rejection rate costs approximately $500,000 per year on a 16-million-unit line. DROFEN eliminates this risk through turnkey delivery - supplying both the pre-assembly and final assembly equipment as a single coordinated system.

 

Q: How long does it take to commission a pen injector pre-assembly line?

A: A complete pen injector pre-assembly line project typically takes 8–10 months from kick-off to production-ready SAT completion. The timeline includes: URS finalization (2–4 weeks), design and engineering (8–12 weeks), manufacturing (12–16 weeks), FAT at DROFEN's facility (4–6 weeks), shipping and installation (2–4 weeks), and SAT at the customer's site (4–6 weeks).

DROFEN MACHINERY EQUIPMENT CO., LTD specializes in the design and delivery of high-speed precision assembly systems for injectable drug delivery devices. The company's core engineering competence lies in solving the unique challenges of assembling complex, multi-component plastic mechanisms at speeds exceeding 150 ppm - where micron-level tolerances, sub-Newton force control, and 100% in-process verification must coexist with sustained production throughput. DROFEN serves global CDMOs and pharmaceutical OEMs seeking to internalize pen injector manufacturing capability without the 3–5 year learning curve typically required to master high-speed mechanism assembly.

 

Published in: Pharmaceutical Technology (June 2026) - "Overcoming Capability Bottlenecks in High-Speed Pen Injector Pre-Assembly"

Contact: www.drofen-pharma.com

Achieving a 160 ppm throughput with >95% yield requires a vision inspection system that is both incredibly fast and highly reliable. DROFEN's approach to vision in pre-assembly goes far beyond simple presence/absence detection. This appendix details the specific vision algorithms and hardware configurations utilized in the platform.

 

The foundation of the vision system is the hardware. At 160 ppm, the system has less than 375 milliseconds per cycle to index the pallet, stabilize the component, trigger the camera, acquire the image, process the algorithm, and communicate the pass/fail result to the Siemens PLC.

 

To achieve this, DROFEN utilizes high-speed industrial cameras with global shutters. Global shutters expose the entire sensor simultaneously, eliminating the "jello effect" or motion blur that occurs with rolling shutters when inspecting moving objects. The cameras are paired with telecentric lenses. Telecentric lenses maintain constant magnification regardless of the object's distance from the lens (within the depth of field). This is crucial for dimensional measurements and alignment checks, as slight variations in the seating height of a component will not artificially alter its apparent size in the image.

 

Lighting is equally critical. The system employs specialized LED lighting arrays, including dome lights for diffuse, shadow-free illumination of highly reflective plastic components, and low-angle ring lights to highlight specific edges or embossed features like the "Zero Marking." The lighting is strobed, synchronized precisely with the camera exposure to freeze motion and maximize image contrast.

 

The vision software utilizes a combination of traditional machine vision tools and advanced pattern recognition algorithms.

Geometric Pattern Matching: This is used extensively for orientation verification. The system is trained on a "golden image" of a correctly oriented component (e.g., the Lead Screw). During production, the algorithm searches for this specific geometric pattern within the field of view, regardless of its exact X-Y position or rotation. It calculates a correlation score, and if the score falls below a validated threshold, the part is rejected. This is highly effective for detecting inverted or incorrectly rotated components.

 

Edge Detection and Caliper Tools: These tools are used to measure the distance between specific features or to verify rotational alignment. For example, to verify the alignment of internal gears, the system uses edge detection to locate the teeth of the gear and measures their angular position relative to a fixed reference mark on the pallet or the outer body.

 

Color Histogram Analysis: For variant management (e.g., verifying the correct color of the Dose Setting Knob), the system uses color histogram analysis. It analyzes the distribution of color pixels within a defined Region of Interest (ROI) and compares it to the validated color profile for the active recipe. This approach is robust against slight variations in ambient lighting or minor color lot differences from the component supplier.

 

In pharmaceutical manufacturing, a "False Accept" (passing a defective unit) is a critical failure that can lead to patient harm or the loss of a high-value drug cartridge downstream. Therefore, the vision system is inherently biased towards "False Rejects" (rejecting a good unit).

However, an excessively high false reject rate will decimate the OEE and yield of the machine. DROFEN mitigates this through rigorous algorithm optimization during the FAT/SAT phases. The system is challenged with thousands of known-good parts to establish a tight statistical baseline for normal variation. The acceptance thresholds are then set just outside this baseline, maximizing defect detection while minimizing false rejects.

The validation of a 160 ppm pre-assembly system is a complex undertaking that requires a structured, documented approach. DROFEN strictly adheres to the ISPE GAMP 5 (Good Automated Manufacturing Practice) V-model lifecycle.

 

The V-model provides a logical framework linking the specification phases with the corresponding testing phases.

Left Side of the V (Specification and Design):

 

Right Side of the V (Testing and Qualification): 4. Design Qualification (DQ): A formal review ensuring the FS and HDS/SDS satisfy all requirements outlined in the URS before manufacturing begins. 5. Installation Qualification (IQ): Verification that the equipment is installed exactly as specified in the HDS (e.g., checking part numbers, wiring connections, P&ID diagrams). 6. Operational Qualification (OQ): Verification that the equipment operates according to the FS throughout all operating ranges. This includes testing all alarms, interlocks, and security access levels.

7. Performance Qualification (PQ): Verification that the equipment consistently produces acceptable product under normal operating conditions. This is where the 160 ppm throughput and 85% OEE are formally proven.

 

A cornerstone of DROFEN's OQ and PQ testing is the "Challenge Parts" methodology. It is not enough to simply run good parts through the machine; the system must prove it can reliably detect and reject bad parts.

 

During FAT and SAT, DROFEN engineers introduce specially manufactured or selected defective parts into the component feed streams. These challenge parts might include:

 

The system must successfully identify and reject 100% of these challenge parts without falsely rejecting the surrounding good parts. This rigorous testing provides the documented evidence required by regulatory bodies that the pre-assembly system is a reliable quality gate.

 

The validation of the Siemens PLC and HMI software is a critical component of the GAMP 5 lifecycle. The software is categorized (typically Category 4 or 5 under GAMP 5), dictating the level of rigor required.

 

Validation includes comprehensive testing of the 21 CFR Part 11 compliance features:

 

This rigorous software validation ensures the data integrity of the pre-assembly process, which is essential for final batch release.

Sustaining a 160 ppm throughput over a 10-year equipment lifecycle requires maintenance strategies that go far beyond reactive repair. The DROFEN pre-assembly platform is designed to support proactive and predictive maintenance methodologies, maximizing uptime and protecting the capital investment.

 

Traditional preventive maintenance relies on calendar-based or cycle-based schedules (e.g., replacing a bearing every 6 months or 5 million cycles). While better than reactive maintenance, this approach often results in replacing perfectly good components prematurely, increasing spare parts costs and unnecessary downtime.

 

The DROFEN platform facilitates a transition towards predictive maintenance (PdM). PdM relies on continuous condition monitoring to identify the early warning signs of component degradation, allowing maintenance to be scheduled before a failure occurs, but only when it is actually needed.

 

The Siemens control architecture continuously monitors several critical parameters that serve as leading indicators of mechanical wear:

Servo Motor Torque Profiles: The system monitors the torque required by the main drive servo motors to execute their motion profiles. A gradual increase in the required torque over time often indicates increasing friction in the cam mechanisms, linear guides, or bearings, signaling the need for lubrication or impending component failure. The PLC can be configured to trigger a "Maintenance Warning" alarm if the average torque exceeds a predefined baseline.

 

Pneumatic Actuation Times: For the remaining pneumatic actuators in the system (e.g., specific reject gates or transfer slides), the PLC monitors the time it takes for the cylinder to travel from the home sensor to the end-of-stroke sensor. An increase in actuation time can indicate a failing seal within the cylinder, a sticking valve, or a drop in the main air supply pressure.

 

Vibratory Feeder Tuning: The system monitors the amplitude and frequency required to maintain the optimal feed rate in the vibratory bowls. Significant deviations from the baseline tuning parameters can indicate wear on the feeder springs, a loose mounting bolt, or changes in the physical characteristics of the incoming components.

 

The Advantech HMI is a critical tool for the maintenance team. It provides dedicated maintenance screens that display the real-time condition monitoring data in easy-to-understand graphical formats.

 

Furthermore, the HMI includes integrated diagnostic tools. When a fault occurs, the HMI does not merely display a cryptic error code. It provides a 3D rendering of the affected station, highlights the specific sensor or actuator that triggered the fault, and provides step-by-step troubleshooting guidance. This significantly reduces the Mean Time to Repair (MTTR), which is a crucial factor in maintaining the ≥85% OEE target.

 

DROFEN provides a comprehensive recommended spare parts list categorized by criticality and expected wear life. The modular design of the pre-assembly platform simplifies spare parts management, as many of the cam mechanisms, servo drives, and sensor arrays are standardized across different stations.

 

Furthermore, DROFEN offers long-term lifecycle support, including remote diagnostic capabilities via secure VPN connections. This allows DROFEN engineers to assist the customer's maintenance team with complex troubleshooting, software updates, and process optimization without the delays associated with dispatching field service personnel.

The decision to invest in a high-performance pre-assembly platform is fundamentally an economic one. This appendix provides a detailed analysis of the Total Cost of Ownership (TCO) and Return on Investment (ROI) factors associated with the DROFEN 160 ppm architecture.

 

While the initial Capital Expenditure (CAPEX) for a sophisticated, cam-driven, 130-pallet pre-assembly system equipped with Keyence LVDT and Kistler force monitoring is higher than that of a basic, pneumatically-driven indexing dial machine, the Operational Expenditure (OPEX) advantages rapidly offset the initial price difference.

 

The primary OPEX drivers in pen injector manufacturing are:

 

A basic, rigidly linked assembly machine running at high speeds requires constant operator attention. Minor jams in vibratory feeders will instantly stop the entire machine, requiring an operator to intervene immediately to resume production. This often necessitates dedicating one operator to every 3-4 stations.

 

The DROFEN 130-pallet architecture fundamentally changes this dynamic. The large circulating buffer decouples the stations. If a minor feed jam occurs, the upstream stations continue to fill the buffer, and the downstream stations continue to draw from it. The machine does not stop. The HMI alerts the operator to the specific feeder issue, and the operator has a window of time (often several minutes) to clear the jam while the machine continues producing good parts at 160 ppm.

 

This decoupling allows a single operator to manage a much larger section of the machine. A complete DROFEN pre-assembly line typically requires only 2-3 operators per shift, significantly reducing long-term labor OPEX compared to less sophisticated architectures.

 

As highlighted in Section 11, the most significant financial justification for the DROFEN platform is its ability to prevent defective pre-assemblies from reaching the final assembly line.

 

Consider a production scenario:

 

If the basic machine allows 1.5% of defective pre-assemblies to reach final assembly, those units will fail the final functional test, resulting in the loss of the $6.00 drug cartridge. Annual Cost of Escaped Defects (Basic Machine): 16,300,000 * 0.015 * $6.00 = $1,467,000.

If the DROFEN platform, utilizing Keyence LVDT and Kistler force monitoring, reduces the escape rate to 0.1%: Annual Cost of Escaped Defects (DROFEN Platform): 16,300,000 * 0.001 * $6.00 = $97,800.

The advanced verification capabilities of the DROFEN platform generate an annual OPEX saving of $1,369,200 purely in avoided drug product waste. This saving alone typically justifies the CAPEX premium of the advanced equipment within the first year of operation.

 

Overall Equipment Effectiveness (OEE) is a measure of availability, performance, and quality. The DROFEN platform's target OEE of ≥85% is achieved through the combination of cam-driven reliability, the 130-pallet buffer, and intelligent consecutive error management.

 

A machine running at 160 ppm with an OEE of 85% produces significantly more saleable product per year than a machine running at 160 ppm with an OEE of 65%. In a market with high demand for GLP-1 therapies, every additional good pen produced represents direct revenue. The higher OEE of the DROFEN platform maximizes the revenue-generating potential of the manufacturing floor space.

The deployment of a highly sophisticated, 160 ppm pre-assembly platform represents a significant technological leap for many pharmaceutical manufacturing facilities. The ultimate success of this investment-measured in sustained OEE and product quality-is inextricably linked to the competence and confidence of the personnel operating and maintaining the equipment. DROFEN MACHINERY recognizes that delivering world-class hardware is only half the solution; delivering comprehensive, structured training is the other.

 

DROFEN's training philosophy shifts the paradigm from "operator as machine tender" to "operator as process owner." In a high-speed, 130-pallet architecture, the machine is designed to handle the routine assembly tasks autonomously. The operator's primary role is to manage the material flow, monitor the HMI for early warning signs of process deviation, and respond swiftly and accurately to the intelligent alarms generated by the Siemens control system.

 

This requires a deep understanding not just of which button to press, but why the machine behaves the way it does. Training programs are designed to demystify the complex technologies-such as the Keyence LVDT dimensional checks and the Kistler force-displacement monitoring-empowering operators to make informed decisions rather than simply reacting to red lights.

 

The training program is integrated into the overall project lifecycle, ensuring that personnel are fully prepared before the equipment enters commercial production.

 

Phase 1: FAT Participation (The Foundation)

Training begins during the Factory Acceptance Testing (FAT) at DROFEN's facility. Key customer personnel (typically lead operators and senior maintenance technicians) are invited to participate actively in the FAT execution. This provides hands-on experience with the equipment in a controlled environment, allowing them to understand the fundamental architecture, the HMI navigation, and the basic operating principles of the cam-driven transport and vibratory feeding systems.

 

Phase 2: SAT and Commissioning (Hands-On Mastery)

The most intensive training occurs during the Site Acceptance Testing (SAT) and commissioning phase at the customer's facility. DROFEN engineers conduct structured classroom sessions combined with extensive on-machine practical exercises.

 

Phase 3: Production Ramp-Up Support (Confidence Building)

Following the successful completion of the SAT, DROFEN provides embedded engineering support during the initial production ramp-up. This "shadowing" phase is critical for building operator confidence. DROFEN experts are on hand to observe the newly trained personnel, correct any deviations from the SOPs, and provide immediate guidance when complex or unprecedented faults occur. This ensures a smooth transition from the controlled testing environment to the realities of a three-shift commercial production schedule.

 

Training does not end when the DROFEN engineers leave the site. The Advantech HMI is designed to serve as an ongoing, interactive training aid.

 

The pharmaceutical landscape is dynamic, and the equipment used to manufacture drug delivery devices must evolve to meet emerging challenges. DROFEN MACHINERY continuously monitors industry trends to ensure its pre-assembly platforms remain at the cutting edge of technological capability.

 

The development of new biologic therapies, particularly in the oncology and immunology sectors, is leading to formulations with significantly higher viscosities than traditional insulin or early-generation GLP-1 agonists. These highly viscous drugs require greater force to inject, which in turn necessitates stronger, more robust internal mechanisms within the pen injector.

 

This trend directly impacts pre-assembly. The equipment must be capable of handling and assembling components manufactured from advanced, high-strength polymers or even metal alloys. Furthermore, the Kistler force monitoring systems must be calibrated to verify these higher operating forces, ensuring that the assembled mechanism can reliably deliver the viscous drug without mechanical failure or excessive patient effort. DROFEN's use of piezoelectric load cells provides the wide dynamic range necessary to adapt to these evolving force requirements.

 

The next generation of pen injectors will increasingly incorporate electronic connectivity (e.g., Bluetooth or NFC) to track dosing history and communicate with patient smartphones or healthcare provider networks.

 

The pre-assembly of these "smart" pens introduces entirely new complexities. The equipment must now handle delicate electronic components-such as micro-switches, flexible printed circuit boards (PCBs), and coin-cell batteries-in addition to the traditional mechanical plastic parts. The vision systems must be upgraded to inspect solder joints and component placement on the PCBs, and new functional testing stations must be integrated to verify the electronic connectivity and battery voltage before the unit proceeds to final assembly. DROFEN's modular cell architecture (discussed in Section 2.3) is specifically designed to accommodate these new integration requirements, allowing electronic assembly cells to be added to the existing mechanical platform.

 

While the current platform utilizes predictive maintenance based on defined thresholds, the future lies in the application of Artificial Intelligence (AI) and Machine Learning (ML) to the massive datasets generated by the pre-assembly process.

 

By aggregating the data from the Keyence LVDT sensors, Kistler load cells, servo torque profiles, and vision systems across multiple machines and multiple facilities, AI algorithms can identify subtle, complex correlations that human engineers might miss. For example, an AI model might discover that a specific combination of ambient humidity, a slight deviation in the plunger cap height (still within tolerance), and a minor increase in the press force consistently predicts a higher likelihood of a dosing accuracy failure downstream. This level of predictive insight will allow manufacturers to continuously optimize the pre-assembly process, pushing yields ever closer to 100% and further reducing the Total Cost of Ownership. The OPC UA architecture integrated into the DROFEN platform provides the essential data pipeline required to feed these future AI-driven analytics systems.

 

For manufacturers seeking an insulin pen assembly machine dedicated to the pre-assembly phase, this guide details the cam-driven architecture, vibratory bowl feeding systems, and force-displacement monitoring required to achieve consistent 160 PPM output with zero-defect quality.